Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Actinogen Medical ( (AU:ACW) ) has provided an announcement.
Actinogen Medical has applied to the ASX for quotation of 4,695,960 new fully paid ordinary shares, to be issued on 8 January 2026 under the code ACW. The additional securities, arising from the exercise or conversion of existing options or other convertible instruments, modestly expand the company’s listed share base and may provide incremental funding flexibility and liquidity for shareholders as Actinogen progresses its development activities.
The most recent analyst rating on (AU:ACW) stock is a Buy with a A$0.08 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
More about Actinogen Medical
Actinogen Medical Limited is an Australia-listed biotechnology company (ASX: ACW) operating in the medical sector, focused on the development of therapeutic products. The company’s activities centre on advancing its pipeline of medical treatments and technologies within the broader healthcare and life sciences market.
Average Trading Volume: 4,678,177
Technical Sentiment Signal: Buy
Current Market Cap: A$210.3M
Find detailed analytics on ACW stock on TipRanks’ Stock Analysis page.